<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36515702</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Genotype-phenotype characterisation of long survivors with motor neuron disease in Scotland.</ArticleTitle><Pagination><StartPage>1702</StartPage><EndPage>1712</EndPage><MedlinePgn>1702-1712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11505-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We investigated the phenotypes and genotypes of a cohort of 'long-surviving' individuals with motor neuron disease (MND) to identify potential targets for prognostication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were recruited via the Clinical Audit Research and Evaluation for MND (CARE-MND) platform, which hosts the Scottish MND Register. Long survival was defined as&#x2009;&gt;&#x2009;8&#xa0;years from diagnosis. 11 phenotypic variables were analysed. Whole genome sequencing (WGS) was performed and variants within 49 MND-associated genes examined. Each individual was screened for C9orf72 repeat expansions. Data from ancestry-matched Scottish populations (the Lothian Birth Cohorts) were used as controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">58 long survivors were identified. Median survival from diagnosis was 15.5&#xa0;years. Long survivors were significantly younger at onset and diagnosis than incident patients and had a significantly longer diagnostic delay. 42% had the MND subtype of primary lateral sclerosis (PLS). WGS was performed in 46 individuals: 14 (30.4%) had a potentially pathogenic variant. 4 carried the known SOD1 p.(Ile114Thr) variant. Significant variants in FIG4, hnRNPA2B1, SETX, SQSTM1, TAF15, and VAPB were detected. 2 individuals had a variant in the SPAST gene suggesting phenotypic overlap with hereditary spastic paraplegia (HSP). No long survivors had pathogenic C9orf72 repeat expansions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long survivors are characterised by younger age at onset, increased prevalence of PLS and longer diagnostic delay. Genetic analysis in this cohort has improved our understanding of the phenotypes associated with the SOD1 variant p.(Ile114Thr). Our findings confirm that pathogenic expansion of C9orf72 is likely a poor prognostic marker. Genetic screening using targeted MND and/or HSP panels should be considered in those with long survival, or early-onset slowly progressive disease, to improve diagnostic accuracy and aid prognostication.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leighton</LastName><ForeName>Danielle J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0003-2015-7198</Identifier><AffiliationInfo><Affiliation>School of Psychology &amp; Neuroscience, University of Glasgow, Glasgow, UK. Danielle.leighton@glasgow.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK. Danielle.leighton@glasgow.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK. Danielle.leighton@glasgow.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. Danielle.leighton@glasgow.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK. Danielle.leighton@glasgow.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Morad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>South East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleary</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>South East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colville</LastName><ForeName>Shuna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephenson</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larraz</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Micheala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carod Artal</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, NHS Highland, Inverness, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Callum</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, NHS Tayside, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swingler</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deary</LastName><ForeName>Ian J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Lothian Birth Cohorts Group, Department of Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porteous</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>South East Scotland Genetics Service, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aitman</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorrie</LastName><ForeName>George H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Lothian Birth Cohorts Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>and the CARE-MND Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SGP/2</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_15080</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SGP/1</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K026992/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.6.1.1</RegistryNumber><NameOfSubstance UI="C400283">SPAST protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.3</RegistryNumber><NameOfSubstance UI="D000074181">Spastin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C522215">FIG4 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015419" MajorTopicYN="Y">Spastic Paraplegia, Hereditary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074181" MajorTopicYN="N">Spastin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prendergast</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russ</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Adele</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deary</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bethell</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Byrne</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flett</LastName><ForeName>Moira</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haagendrud</LastName><ForeName>Hanne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hafezi</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatrick</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchison</LastName><ForeName>Aidan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lennox</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAleer</LastName><ForeName>Dympna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McEleney</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millar</LastName><ForeName>Kitty</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murrie</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perry</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saravanan</LastName><ForeName>Gowri</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starrs</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Storey</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stott</LastName><ForeName>Gill</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thornton</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Der Westhuizen</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Webber</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36515702</ArticleId><ArticleId IdType="pmc">PMC9971124</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11505-0</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11505-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leighton D, Newton J, Colville S, et al. Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Front Degener. 2019 doi: 10.1080/21678421.2019.1582673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582673</ArticleId><ArticleId IdType="pubmed">30889975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chancellor AM, Slattery JM, Fraser H, et al (1993) The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 240:339&#x2013;46. http://www.ncbi.nlm.nih.gov/pubmed/8336173. Accessed 22 May 2016</Citation><ArticleIdList><ArticleId IdType="pubmed">8336173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward C, Swingler RJ, Simpson SA, et al (1996) A specific superoxide dismutase mutation is on the same genetic background in sporadic and familial cases of amyotrophic lateral sclerosis. Am J Hum Genet 59:1165&#x2013;1167. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1914828&amp;tool=pmcentrez&amp;rendertype=abstract. Accessed 24 Feb 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914828</ArticleId><ArticleId IdType="pubmed">8900247</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton DJ, Newton J, Stephenson LJ, et al. Changing epidemiology of motor neurone disease in Scotland. J Neurol. 2019;266:817&#x2013;825. doi: 10.1007/s00415-019-09190-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09190-7</ArticleId><ArticleId IdType="pubmed">30805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:178.e11&#x2013;178.e20. doi: 10.1016/j.neurobiolaging.2016.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.12.013</ArticleId><ArticleId IdType="pmc">PMC5302213</ArticleId><ArticleId IdType="pubmed">28089114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateen FJ, Carone M, Sorenson EJ. Patients who survive 5 years or more with ALS in Olmsted County, 1925&#x2013;2004. J Neurol Neurosurg Psychiatry. 2010;81:1144&#x2013;1146. doi: 10.1136/jnnp.2009.201251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.201251</ArticleId><ArticleId IdType="pmc">PMC2946435</ArticleId><ArticleId IdType="pubmed">20627966</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King&#x2019;s database 1990&#x2013;2002. J Neurol Neurosurg Psychiatry. 2003;74:995&#x2013;997. doi: 10.1136/jnnp.74.7.995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.7.995</ArticleId><ArticleId IdType="pmc">PMC1738535</ArticleId><ArticleId IdType="pubmed">12810805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Messina P, Logroscino G, et al. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol. 2014;75:287&#x2013;297. doi: 10.1002/ana.24096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24096</ArticleId><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci. 2008;268:28&#x2013;32. doi: 10.1016/j.jns.2007.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.10.023</ArticleId><ArticleId IdType="pubmed">18021808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Nagy PL, Gennings C, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015;1:e3. doi: 10.1212/01.NXG.0000464294.88607.dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.NXG.0000464294.88607.dd</ArticleId><ArticleId IdType="pmc">PMC4821084</ArticleId><ArticleId IdType="pubmed">27066542</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91:373&#x2013;377. doi: 10.1136/jnnp-2019-322541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId><ArticleId IdType="pmc">PMC7147236</ArticleId><ArticleId IdType="pubmed">32029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285&#x2013;291. doi: 10.1038/nature19057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19057</ArticleId><ArticleId IdType="pmc">PMC5018207</ArticleId><ArticleId IdType="pubmed">27535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaastra B, Shatunov A, Pulit S, et al. Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2016;17:593&#x2013;599. doi: 10.1080/21678421.2016.1213852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1213852</ArticleId><ArticleId IdType="pmc">PMC5125285</ArticleId><ArticleId IdType="pubmed">27584932</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Corcia P, Harms MB, et al. Genetics of primary lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2020;21:28&#x2013;34. doi: 10.1080/21678421.2020.1837177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1837177</ArticleId><ArticleId IdType="pubmed">33602012</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugman F, Veldink JH, Franssen H, et al. Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol. 2009;66:509&#x2013;514. doi: 10.1001/archneurol.2009.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.19</ArticleId><ArticleId IdType="pubmed">19364936</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AM, Pattie A, Deary IJ. Cohort profile update: the lothian birth cohorts of 1921 and 1936. Int J Epidemiol. 2018;47:1042&#x2013;1042r. doi: 10.1093/ije/dyy022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy022</ArticleId><ArticleId IdType="pmc">PMC6124629</ArticleId><ArticleId IdType="pubmed">29546429</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Shing SLH, et al. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Front Degener. 2019;20:133&#x2013;145. doi: 10.1080/21678421.2018.1550518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550518</ArticleId><ArticleId IdType="pubmed">30654671</ArticleId></ArticleIdList></Reference><Reference><Citation>Scottish Genome Partnership (2020) Scottish Genome Partnership: rare disease research studies. Scottish Genome Partnersh. https://www.scottishgenomespartnership.org/sgp-rare-disease-research-studies. Accessed 1 Jun 2020</Citation></Reference><Reference><Citation>Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Published Online First: 16 March 2013.http://arxiv.org/abs/1303.3997. Accessed 1 Nov 2018</Citation></Reference><Reference><Citation>Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics. 2014;30:2503&#x2013;2505. doi: 10.1093/bioinformatics/btu314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu314</ArticleId><ArticleId IdType="pmc">PMC4147885</ArticleId><ArticleId IdType="pubmed">24812344</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297&#x2013;1303. doi: 10.1101/gr.107524.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Auwera GA, Carneiro MO, Hartl C, et al (2013) From fastq data to high-confidence variant calls: the genome analysis toolkit best practices pipeline. In: Current Protocols in bioinformatics. Wiley, Hoboken, pp 11.10.1&#x2013;11.10.33. 10.1002/0471250953.bi1110s43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4243306</ArticleId><ArticleId IdType="pubmed">25431634</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden Helix I (2018) VarSeq. Golden Helix, Inc, Bozeman, MT. http://goldenhelix.com. Accessed 11 Nov 2018</Citation></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;443. doi: 10.1038/s41586-020-2308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wu C, Li C, et al. dbNSFP v3.0: a one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat. 2016;37:235&#x2013;241. doi: 10.1002/humu.22932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22932</ArticleId><ArticleId IdType="pmc">PMC4752381</ArticleId><ArticleId IdType="pubmed">26555599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 2014;42:13534&#x2013;13544. doi: 10.1093/nar/gku1206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gku1206</ArticleId><ArticleId IdType="pmc">PMC4267638</ArticleId><ArticleId IdType="pubmed">25416802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary EM, Pal S, Azam T, et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Mol Cell Probes. 2016;30:218&#x2013;224. doi: 10.1016/j.mcp.2016.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC4978699</ArticleId><ArticleId IdType="pubmed">27288208</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellard S, Baple EL, Callaway A, et al (2020) ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020. Assoc Clin Genomic Sci Published Online First. https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf. Accessed 1 Nov 2020</Citation></Reference><Reference><Citation>Jarvik GP, Browning BL. Consideration of cosegregation in the pathogenicity classification of genomic variants. Am J Hum Genet. 2016;98:1077&#x2013;1081. doi: 10.1016/j.ajhg.2016.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC4908147</ArticleId><ArticleId IdType="pubmed">27236918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavtigian SV, Greenblatt MS, Harrison SM, et al. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20:1054&#x2013;1060. doi: 10.1038/gim.2017.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.210</ArticleId><ArticleId IdType="pmc">PMC6336098</ArticleId><ArticleId IdType="pubmed">29300386</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team (2017) R: a language and environment for statistical computing. R Found Stat Comput. http://www.r-project.org/. Accessed 1 Nov 2018</Citation></Reference><Reference><Citation>Kapeli K, Pratt GA, Vu AQ, et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat Commun. 2016;7:12143. doi: 10.1038/ncomms12143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12143</ArticleId><ArticleId IdType="pmc">PMC4935974</ArticleId><ArticleId IdType="pubmed">27378374</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, et al. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun. 2016;4:70. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68:1440&#x2013;1446. doi: 10.1001/archneurol.2011.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Shu S, Wang RR, et al. Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS. Neurology. 2016;87:1763&#x2013;1769. doi: 10.1212/WNL.0000000000003256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003256</ArticleId><ArticleId IdType="pubmed">27694260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang Y-D, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473. doi: 10.1038/nature11922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinVar. ClinVar. Natl. Cent. Biotechnol. Information, U.S. Natl. Libr. Med. 2016. https://www.ncbi.nlm.nih.gov/clinvar/. Accessed 2 Nov 2018</Citation></Reference><Reference><Citation>Svenson IK, Ashley-Koch AE, Gaskell PC, et al. Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. Am J Hum Genet. 2001;68:1077&#x2013;1085. doi: 10.1086/320111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/320111</ArticleId><ArticleId IdType="pmc">PMC1226088</ArticleId><ArticleId IdType="pubmed">11309678</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253:1428&#x2013;1436. doi: 10.1007/s00415-006-0226-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0226-8</ArticleId><ArticleId IdType="pubmed">16773270</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease (2001) Natl Inst Heal Care Excell, pp 1&#x2013;13. https://www.nice.org.uk/guidance/ta20/documents/riluzole-appeal-against-guidance-dated-december-2000. Accessed 29 Aug 2019</Citation></Reference><Reference><Citation>Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2007;64:232. doi: 10.1001/archneur.64.2.232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.2.232</ArticleId><ArticleId IdType="pubmed">17296839</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;240. doi: 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PR, Iacoangeli A, Opie-Martin S, et al. The impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain. 2022 doi: 10.1093/brain/awac279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac279</ArticleId><ArticleId IdType="pmc">PMC9762932</ArticleId><ArticleId IdType="pubmed">36162820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>